Recombinant Zebrafish ANXA2A

• Cat.No.: ANXA2A-9639Z
• Product Overview: Recombinant Zebrafish ANXA2A full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: anxa2a annexin A2a [ Danio rerio (zebrafish) ]
• Official Symbol: ANXA2A
• Gene ID: 325557
• mRNA Refseq: NM_181761
• Protein Refseq: NP_861426
• UniProt ID: Q804G9

Reviews

05/23/2022

Not only does it provide reliable and consistent results due to its high quality and purity, but it also holds significant value in understanding cellular processes and disease mechanisms.

03/10/2020

Coupled with the manufacturer's exceptional technical support and commitment to customer satisfaction, researchers can confidently utilize the ANXA2A protein in their studies, knowing that they have the necessary resources and assistance to succeed.

01/27/2020

This commitment to excellence ensures that researchers are provided with the most advanced and reliable tools for their investigations.

09/23/2019

the ANXA2A protein offers numerous advantages in trials and research experiments.

Q&As

How does ANXA2A contribute to tumor invasion and metastasis?

ANXA2A promotes tumor invasion and metastasis through multiple mechanisms. It is involved in the formation of invadopodia, which are protrusive structures on the surface of cancer cells that facilitate matrix degradation and invasion. ANXA2A interacts with actin filaments and regulates the assembly and stability of invadopodia, promoting their formation and function.

Are there any known mutations or alterations in the ANXA2A gene associated with diseases?

There have been reports of genetic alterations and mutations in the ANXA2A gene associated with certain diseases. For example, mutations in ANXA2A have been observed in individuals with idiopathic dilated cardiomyopathy, a condition characterized by weakened heart muscle function. However, the understanding of the specific role of ANXA2A mutations in disease development is still being investigated.

What are the interactions or partnerships of ANXA2A with other proteins?

ANXA2A interacts with different proteins and molecules to carry out its functions. It can bind to actin filaments, enabling its involvement in cytoskeleton organization and cell motility processes. ANXA2A also interacts with other annexin family members, such as ANXA1 and ANXA5. Additionally, it can form complexes with various membrane receptors, integrins, and proteins involved in vesicle trafficking.

Can ANXA2A be targeted for cancer therapy?

ANXA2A has emerged as a potential target for cancer therapy due to its involvement in tumor progression and metastasis. Several strategies have been explored to target ANXA2A in preclinical studies. These include inhibiting ANXA2A expression using siRNAs or antisense oligonucleotides, blocking ANXA2A receptor interactions using small molecules or antibodies, and disrupting ANXA2A-actin interactions.

Is ANXA2A involved in neurodegenerative diseases other than Alzheimer's?

ANXA2A has been implicated in neurodegenerative diseases other than Alzheimer's disease. It has been found to be upregulated in Parkinson's disease and Huntington's disease, suggesting its potential involvement in the pathogenesis of these conditions. ANXA2A may contribute to the accumulation of misfolded proteins and neuroinflammation in neurodegenerative diseases.

Can ANXA2A be used as a biomarker for cancer?

ANXA2A has been proposed as a potential biomarker for cancer due to its dysregulated expression in various types of cancer. Increased ANXA2A expression has been associated with poor prognosis in certain cancers, such as breast, lung, colorectal, and ovarian cancers. However, further research is needed to validate ANXA2A as a reliable biomarker for cancer diagnosis and prognosis.

Does ANXA2A play a role in diseases?

Yes, ANXA2A has been implicated in various diseases. It is often overexpressed in cancer cells and has been associated with increased invasion, metastasis, and drug resistance. ANXA2A has also been implicated in neurodegenerative diseases, including Alzheimer's disease, where it may contribute to amyloid plaque formation. Additionally, ANXA2A has been linked to cardiovascular diseases, inflammation, and autoimmune disorders.

Is ANXA2A involved in cellular signaling pathways?

Yes, ANXA2A is involved in cellular signaling pathways. It can modulate the activity of protein kinases, including protein kinase C (PKC) and tyrosine kinases, and participate in intracellular signaling cascades. ANXA2A's involvement in signaling pathways can vary depending on the cellular context and its interacting partners.

How is ANXA2A involved in cancer?

ANXA2A is often overexpressed in cancer cells and plays a significant role in cancer progression. It has been implicated in tumor invasion, metastasis, and angiogenesis. ANXA2A promotes cancer cell migration by interacting with actin filaments and regulating the formation of invadopodia, which are specialized structures that allow cancer cells to degrade extracellular matrix and invade surrounding tissues. ANXA2A also interacts with membrane receptors and integrins, promoting adhesion and migration of cancer cells. Additionally, ANXA2A has been shown to play a role in drug resistance, potentially making it a therapeutic target in cancer treatment.

Are there any known inhibitors or drugs targeting ANXA2A?

The development of specific inhibitors targeting ANXA2A is still ongoing. However, certain molecules have been found to inhibit ANXA2A functions indirectly. For example, some compounds that inhibit protein kinase C (PKC) have been shown to disrupt ANXA2A phosphorylation and its interaction with other proteins. ANXA2A-associated processes, such as cancer cell migration and invasion, have also been targeted using approaches like small interfering RNAs (siRNAs) to specifically knockdown ANXA2A expression.